Trade Summary

Yesterday, Meyer Andrew Hollman, serving as Chief Business Officer at Janux Therapeutics, Inc. (JANX), sold 1,879 shares at $13.73 per share, for a total transaction value of $25,799.00. Following this transaction, Meyer Andrew Hollman now holds 83,095 shares of JANX.

This sale represents a 2.00% decrease in Meyer Andrew Hollman's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Friday, January 2, 2026 and publicly disclosed via SEC Form 4 filing on Friday, January 2, 2026, meaning the disclosure happened on the same day as the trade.

Janux Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.